期刊文献+

应用不同β-受体阻滞剂后青光眼眼动脉血流动力学分析 被引量:1

Assessment of ophthalmic arterial blood flow in glaucomatous eyes treated with beta blockers
原文传递
导出
摘要 目的 :观察应用不同 β -受体阻滞剂后青光眼眼动脉血流动力学变化。方法 :用彩色多普勒检测 2 0例中、晚期开角型青光眼患者 ,应用选择性β1-受体阻滞剂 0 2 5%Betaxolol和非选择性 β-受体阻滞剂 0 5%Timolol,观察治疗前和治疗 2周后眼动脉收缩期峰值血流速度 (PSV)和舒张末期血流速度(EDV)。结果 :只有 0 2 5%Betaxolol治疗组眼动脉舒张末期血流速度 (EDV)治疗前后差异有显著性 (P<0 0 5) ,0 5%Timolol治疗组EDV治疗前后差异无显著性 (P >0 0 5)。结论 :选择性 β1-受体阻滞剂增加EDV ,降低眼动脉舒张期阻力 ,保证了血流灌注。 HT5”SS][WT5”BZ][ST5”BZ]Objective:To investigate the changes of arterial blood flow in primary open angle glaucomatous eyes after treatment with different beta blockers.Methods:20 POAG patients were randomly divided into 2 groups (each group 10 patients) and selective beta blocker,0 25% Betaxolol and non selective beta blockers,0 5% Timolol were applied separately to each group (Betaxolol and Timolol groups).Color doppler ultrasound was used to measure the peak systolic velocity (PSV) and end diastolic velocity (EDV) of arterial blood flow in subjects studied,before and after treatment with beta blockers.Results:In Betaxolol group,there was significant difference (P<0 05) in the end diastolic velocity (EDV) of ophthalmic arterial blood flow between pre treatment and treatment after two weeks,but no significant difference (P>0 05) in Timolol group.Conclusion:The selective beta blockers,0 25%Betaxolol can increase EDV and decrease the vascular resistance in the diastolic phase of ophthalmic artery to the eye,thus improve the blood flow in ophthalmic artery. [HT5”H][WT5”HZ][ST5”HZ]
出处 《眼科》 CAS 2000年第6期349-350,共2页 Ophthalmology in China
关键词 青光眼 肾上腺素能Β受体阻滞剂 眼动脉 血液动力学 glaucoma adrenergic beta receptor blockaders ophthalmic artery hemodynamics
  • 相关文献

参考文献1

二级参考文献3

  • 1侯勤英,中华眼科杂志,1995年,31卷,288页
  • 2张丰菊,实用眼科杂志,1991年,9期,706页
  • 3刘嫣芬(译),国外医学.眼科学分册,1988年,12期,241页

共引文献18

同被引文献12

  • 1李凤鸣.眼科全书[M].北京:人民卫生出版社,1996.2575.
  • 2Nordmann J P,Mertz B,Yannoulis N C. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 Mont
  • 3Grierson I,Marshall J,Robins E. Human Trabecular Meshwork in Primary Culture: A Morphological an Autoradiographic Study [J]. Experimental Eye Research,1983,37:349-365.
  • 4Tripathi R C,Tripathi B J. Human Trabecular Endothelium, Corneal Endothelium, Keratocytes and Scleral Fibroblasts in Primary Cell Culture. A Comparative Study of Growth Characteristics, Morphology, and Phagocytic Activity by Light and Scanning Electron Mi
  • 5Tripathi B J,Tripathi R C. The Glaucomas [M]. St. Louis:C.V. Mosby,1995.
  • 6Betaxolol Hydrochloride 0.5% Ophthalmic Solution USP. http://www.medsafe.govt.nz/Profs/Datasheet/a/ Apo-Betaxololeyedrops.htm.
  • 7Reiss G R,Brubaker R F. The mechanism of betaxolol, a new ocular hypotensive agent [J]. Ophthalmology,1983,90(11):1369-1372.
  • 8Saxena R,Prakash J,Mathur P,Gupta S K. Pharmacotherapy of Glaucoma [J]. Indian Journal of Pharmacology. 2002,34:71-85.
  • 9贾金辰 杨进献.眼科临床常用数值[M].郑州:河南科学技术出版社,1992..
  • 10Lee P Y,Podos S M,Severin C. Effect of Prostaglandin F2α on Aqueous Humor Dynamics of Rabbit, Cat, and Monkey [J]. Investigative Ophthalmology &amp; Visual Science. 1984,25(9):1087-1093.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部